...Phase III testing. Sylentis did not respond to an inquiry regarding tivanisiran’s specific side effects. Neomed Institute...

...include optimizing and testing the compound in other models of depression. Artelo Biosciences Inc. and Neomed Institute...

...molecule antagonist of the purinergic receptor P2X ligand-gated ion channel 3 (P2X3) receptor from the Neomed Institute...

...Quebec) named Max Fehlmann president and CEO, effective Jan. 16. He was CEO at the Neomed Institute...

...control of genes and how cell systems function in healthy and disease states February 2015 Neomed Institute...

...$10 million towards the strategic fund. Neomed also contributed $10 million to the strategic fund. Neomed Institute...

...of concept (POC), at which point they will be out-licensed (see BioCentury, Dec. 3, 2012). Neomed Institute...

...to identify ways to improve care and advance outcomes in type 1 diabetes Epigenetix Inc. Neomed Institute...

...The Neomed Institute has begun development of its first cancer therapeutic, a bromodomain containing 4 inhibitor from...
...Miami, Fla. IntelliSyn , Montreal, Quebec, Canada Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Neomed Institute...

...point they will be out-licensed (see BioCentury, Dec. 3, 2012). Epigenetix Inc. , Miami, Fla. Neomed Institute...